Similar articles for PMID: 26769887

Year	Number of Results
1992	1
2009	1
2010	3
2011	8
2012	20
2013	18
2014	20
2015	24
2016	42
2017	20
2018	27
2019	12
2020	15
2021	1

1

Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective.

Conniff J, Evensen A. Conniff J, et al. J Am Board Fam Med. 2016 Jan-Feb;29(1):143-51. doi: 10.3122/jabfm.2016.01.150223. J Am Board Fam Med. 2016. PMID: 26769887 Free article.

2

What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.

Krakower D, Mayer KH. Krakower D, et al. Ann Intern Med. 2012 Oct 2;157(7):490-7. doi: 10.7326/0003-4819-157-7-201210020-00510. Ann Intern Med. 2012. PMID: 22821365 Free PMC article. Review.

3

Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.

Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, Leite IC, Freitas L, Martins LMS, Torres TS, Vasconcelos R, De Boni RB, Anderson PL, Liu A, Luz PM, Veloso VG; PrEP Brasil Study Team. Grinsztejn B, et al. Lancet HIV. 2018 Mar;5(3):e136-e145. doi: 10.1016/S2352-3018(18)30008-0. Epub 2018 Feb 18. Lancet HIV. 2018. PMID: 29467098 Clinical Trial.

4

Nondaily preexposure prophylaxis for HIV prevention.

Anderson PL, García-Lerma JG, Heneine W. Anderson PL, et al. Curr Opin HIV AIDS. 2016 Jan;11(1):94-101. doi: 10.1097/COH.0000000000000213. Curr Opin HIV AIDS. 2016. PMID: 26633641 Free PMC article. Review.

5

Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States.

Leech AA, Burgess JF, Sullivan M, Kuohung W, Horný M, Drainoni ML, Christiansen CL, Linas BP. Leech AA, et al. AIDS. 2018 Nov 28;32(18):2787-2798. doi: 10.1097/QAD.0000000000002014. AIDS. 2018. PMID: 30234602 Free PMC article.

6

Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.

Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, Marzinke MA, Hendrix CW, Anderson PL, Elharrar V, Stirratt M, Rooney JF, Piwowar-Manning E, Eshleman SH, McKinstry L, Li M, Dye BJ, Grant RM; HPTN 067 (ADAPT) study team. Bekker LG, et al. Lancet HIV. 2018 Feb;5(2):e68-e78. doi: 10.1016/S2352-3018(17)30156-X. Epub 2017 Oct 3. Lancet HIV. 2018. PMID: 28986029 Free PMC article. Clinical Trial.

7

Oral preexposure prophylaxis to prevent HIV infection: clinical and public health implications.

Baker J, OʼHara KM. Baker J, et al. JAAPA. 2014 Dec;27(12):10-7. doi: 10.1097/01.JAA.0000456567.37724.e0. JAAPA. 2014. PMID: 25390822 Review.

8

HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.

Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, Kallas EG, Chariyalertsak S, Grant RM; iPrEx investigators. Deutsch MB, et al. Lancet HIV. 2015 Dec;2(12):e512-9. doi: 10.1016/S2352-3018(15)00206-4. Epub 2015 Nov 6. Lancet HIV. 2015. PMID: 26614965 Free PMC article. Clinical Trial.

9

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

Parikh UM, Mellors JW. Parikh UM, et al. Curr Opin HIV AIDS. 2016 Jan;11(1):49-55. doi: 10.1097/COH.0000000000000209. Curr Opin HIV AIDS. 2016. PMID: 26633640 Free PMC article. Review.

10

HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.

Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR 3rd, Sloan CE, Sax PE, Walensky RP. Paltiel AD, et al. Clin Infect Dis. 2009 Mar 15;48(6):806-15. doi: 10.1086/597095. Clin Infect Dis. 2009. PMID: 19193111 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed